Correction: Statement re Lincense Update

CORRECTION: PROTEOME SCIENCES TMT REAGENTS LICENSE UPDATE

The following replaces the license update released on Thursday 11 August at 16:25

The  full amended text appears below. The amendment is contained in the Enquiries and Notes to Editors
sections

For immediate release

15 August 2005

                             PROTEOME SCIENCES TMT REAGENTS LICENSE UPDATE

The Directors of Proteome Sciences plc announce that the process of concluding a licence agreement for
the  company's Tandem Mass Tags® (TMT®) is continuing satisfactorily, and that a further  announcement
will be made when the deal is formally concluded.

Enquiries:

Proteome Sciences plc                               01932 865065
Christopher Pearce, Chief Executive
James Malthouse, Finance Director

IKON Associates                                     01483 535102
Adrian Shaw

Notes to Editors:

Proteome  Sciences  plc applies high sensitivity proteomics to identify and characterise  differential
protein expression in diseases for diagnostic, prognostic and therapeutic applications. It has to date
developed  sensitive  blood  assays  for  stroke, vCJD, BSE,  solid  organ  transplant  rejection  and
Alzheimer's   disease.   The   main   focus  of  its  research   currently   addresses   neurological,
neurodegenerative, diabetes/obesity, oncology and cardiovascular conditions.

In  addition  to its own proprietary biomarkers, Proteome Sciences has developed ProteoSHOP  (Proteome
Sciences High Output Proteomics), a toolbox that offers high sensitivity and high throughput  gel  and
gel-free  proprietary technologies for the identification of potential biomarkers  and  drug  targets.
These include specialisation in membrane proteins and protein phosphorylation.

The  Company  has  also  developed  a range of specialist reagents  to  improve  the  performance  and
quantitation  of  protein  separation  and characterisation with  mass  spectrometry,  bioinformatics,
statistics and pattern recognition. These include Sensitizer, PST, qPST and TMT.

The  process  of  commercialisation is being actively pursued across the portfolio  of  the  Company's
programmes and technologies and to date licensing deals have been signed for the commercialization  of
tests for Stroke and TSEs.

Proteome  Sciences is headquartered in Cobham, Surrey in the UK and has laboratories at Kings  College
Hospital, London and in Frankfurt. It employs 40 full time scientists in addition to its corporate and
business development staff. The Company is listed on the Alternative Investment Market.

ENDS

Proteome Sciences